Scynexis Inc. (NASDAQ:SCYX) was up 3.4% during trading on Thursday . The company traded as high as $2.16 and last traded at $2.14, with a volume of 223,759 shares trading hands. The stock had previously closed at $2.07.

A number of equities research analysts have recently commented on SCYX shares. Zacks Investment Research cut Scynexis from a “buy” rating to a “hold” rating in a research report on Thursday, July 14th. Brean Capital restated a “buy” rating on shares of Scynexis in a research report on Monday, May 9th. Canaccord Genuity restated a “buy” rating on shares of Scynexis in a research report on Monday, April 18th. Finally, Needham & Company LLC restated a “buy” rating on shares of Scynexis in a research report on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Scynexis has an average rating of “Buy” and an average price target of $12.71.

The firm’s 50-day moving average price is $2.58 and its 200 day moving average price is $3.91. The company’s market cap is $31.29 million.

Scynexis (NASDAQ:SCYX) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. On average, equities research analysts anticipate that Scynexis Inc. will post ($2.27) earnings per share for the current fiscal year.

In other Scynexis news, CFO Eric Francois bought 15,000 shares of Scynexis stock in a transaction dated Friday, June 24th. The stock was acquired at an average cost of $2.39 per share, with a total value of $35,850.00. Following the completion of the acquisition, the chief financial officer now owns 15,000 shares of the company’s stock, valued at $35,850. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gonzalez David Angulo bought 36,950 shares of Scynexis stock in a transaction dated Thursday, June 30th. The stock was acquired at an average cost of $2.22 per share, with a total value of $82,029.00. Following the completion of the acquisition, the insider now directly owns 8,850 shares of the company’s stock, valued at approximately $19,647. The disclosure for this purchase can be found here.

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.